{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:15:14Z","timestamp":1793132114870,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin International, plc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive, renal phosphate-wasting disorder characterized by a pathological increase in FGF23 concentration and activity. Due to its rarity, diagnosis may be delayed, which can adversely affect outcomes. As a chronic disease resulting in progressive accumulation of musculoskeletal manifestations, it is important to understand the natural history of XLH over the patient\u2019s lifetime and the impact of drug treatments and other interventions. This multicentre, international patient registry (International XLH Registry) was established to address the paucity of these data. Here we present the findings of the first interim analysis of the registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The International XLH Registry was initiated in August 2017 and includes participants of all ages diagnosed with XLH, regardless of their treatment and management. At the database lock for this first interim analysis (29 March 2021), 579 participants had entered the registry before 30 November 2020 and are included in the analysis (360 children [62.2%], 217 adults [37.5%] and 2 whose ages were not recorded [0.3%]; 64.2% were female). Family history data were available for 319\/345 (92.5%) children and 145\/187 (77.5%) adults; 62.1% had biological parents affected by XLH. Genetic testing data were available for 341 (94.7%) children and 203 (93.5%) adults; 370\/546 (67.8%) had genetic test results; 331\/370 (89.5%) had a confirmed\n                      <jats:italic>PHEX<\/jats:italic>\n                      mutation. A notably longer time to diagnosis was observed in adults\u2009\u2265\u200950\u00a0years of age (mean [median] duration 9.4 [2.0] years) versus all adults (3.7 [0.1] years) and children (1.0 [0.2] years). Participants presented with normal weight, shorter length or height and elevated body mass index (approximately\u2009\u2212\u20092 and\u2009+\u20092 Z-scores, respectively) versus the general population. Clinical histories were collected for 349 participants (239 children and 110 adults). General data trends for prevalence of bone, dental, renal and joint conditions in all participants were aligned with expectations for a typical population of people with XLH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The data collected within the International XLH Registry, the largest XLH registry to date, provide substantial information to address the paucity of natural history data, starting with demographic, family history, genetic testing, diagnosis, auxology and baseline data on clinical presentation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02882-4","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T23:29:31Z","timestamp":1695770971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-1098","authenticated-orcid":false,"given":"Gema","family":"Ariceta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe Sparre","family":"Beck-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke M.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Lucas Collantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Levtchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"M\u04d3kitie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Zulf","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Tripto-Shkolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carola","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"2882_CR1","doi-asserted-by":"publisher","unstructured":"Javaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K, et al. Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab. 2022;107:e1249\u201362. https:\/\/doi.org\/10.1210\/clinem\/dgab739.","DOI":"10.1210\/clinem\/dgab739"},{"key":"2882_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerini D, Brandi ML. Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos Int. 2021;32:1937\u201349. https:\/\/doi.org\/10.1007\/s00198-021-05997-1.","journal-title":"Osteoporos Int"},{"key":"2882_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009;160:491\u20137. https:\/\/doi.org\/10.1530\/EJE-08-0818.","journal-title":"Eur J Endocrinol"},{"key":"2882_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62:811\u20136. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0275.","journal-title":"Endocr J"},{"key":"2882_CR5","unstructured":"European Union. Rare diseases. https:\/\/ec.europa.eu\/health\/non_communicable_diseases\/rare_diseases_en. Accessed Nov 2021."},{"key":"2882_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, Raeder H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol. 2016;174:125\u201336. https:\/\/doi.org\/10.1530\/EJE-15-0515.","journal-title":"Eur J Endocrinol"},{"key":"2882_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14:58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8.","journal-title":"Orphanet J Rare Dis"},{"key":"2882_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","volume":"15","author":"R Padidela","year":"2020","unstructured":"Padidela R, Nilsson O, Makitie O, Beck-Nielsen S, Ariceta G, Schnabel D, et al. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare Dis. 2020;15:172. https:\/\/doi.org\/10.1186\/s13023-020-01434-4.","journal-title":"Orphanet J Rare Dis"},{"key":"2882_CR9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3:1321\u201334. https:\/\/doi.org\/10.1210\/js.2018-00365.","journal-title":"J Endocr Soc"},{"key":"2882_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","volume":"87","author":"SS Beck-Nielsen","year":"2010","unstructured":"Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int. 2010;87:108\u201319. https:\/\/doi.org\/10.1007\/s00223-010-9373-0.","journal-title":"Calcif Tissue Int"},{"key":"2882_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381\u20138. https:\/\/doi.org\/10.1002\/jbmr.340.","journal-title":"J Bone Miner Res"},{"key":"2882_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","volume":"68","author":"IR Reid","year":"1989","unstructured":"Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine. 1989;68:336\u201352.","journal-title":"Medicine"},{"key":"2882_CR13","doi-asserted-by":"publisher","first-page":"bvab070","DOI":"10.1210\/jendso\/bvab070","volume":"5","author":"M Cheung","year":"2021","unstructured":"Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J. Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc. 2021;5:bvab070. https:\/\/doi.org\/10.1210\/jendso\/bvab070.","journal-title":"J Endocr Soc"},{"key":"2882_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","volume":"17","author":"MIL Yanes","year":"2022","unstructured":"Yanes MIL, Diaz-Curiel M, Peris P, Vicente C, Marin S, Ramon-Krauel M, et al. Health-related quality of life of X-linked hypophosphatemia in Spain. Orphanet J Rare Dis. 2022;17:298. https:\/\/doi.org\/10.1186\/s13023-022-02452-0.","journal-title":"Orphanet J Rare Dis"},{"key":"2882_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","volume":"22","author":"V Saraff","year":"2020","unstructured":"Saraff V, Nadar R, Hogler W. New developments in the treatment of X-linked hypophosphataemia: implications for clinical management. Paediatr Drugs. 2020;22:113\u201321. https:\/\/doi.org\/10.1007\/s40272-020-00381-8.","journal-title":"Paediatr Drugs"},{"key":"2882_CR16","doi-asserted-by":"publisher","first-page":"204201882110011","DOI":"10.1177\/20420188211001150","volume":"12","author":"A Brener","year":"2021","unstructured":"Brener A, Lebenthal Y, Cleper R, Kapusta L, Zeitlin L. Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy. Ther Adv Endocrinol Metab. 2021;12:20420188211001150. https:\/\/doi.org\/10.1177\/20420188211001150.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2882_CR17","unstructured":"European Medicines Agency. CRYSVITA 10 mg solution for injection. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf. Accessed Nov 2021."},{"key":"2882_CR18","unstructured":"US Food and Drug Administration. CRYSVITA (burosumab-twza) injection, for subcutaneous use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761068s004lbl.pdf. Accessed Nov 2021."},{"key":"2882_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15:435\u201355. https:\/\/doi.org\/10.1038\/s41581-019-0152-5.","journal-title":"Nat Rev Nephrol"},{"key":"2882_CR20","doi-asserted-by":"publisher","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","volume":"12","author":"MR Laurent","year":"2021","unstructured":"Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, et al. Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium. Front Endocrinol. 2021;12:641543. https:\/\/doi.org\/10.3389\/fendo.2021.641543.","journal-title":"Front Endocrinol"},{"key":"2882_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","volume":"9","author":"R Padidela","year":"2020","unstructured":"Padidela R, Cheung MS, Saraff V, Dharmaraj P. Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations. Endocr Connect. 2020;9:1051\u20136. https:\/\/doi.org\/10.1530\/EC-20-0291.","journal-title":"Endocr Connect"},{"key":"2882_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1750-1172-9-81","volume":"9","author":"L Viviani","year":"2014","unstructured":"Viviani L, Zolin A, Mehta A, Olesen HV. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis. 2014;9:81. https:\/\/doi.org\/10.1186\/1750-1172-9-81.","journal-title":"Orphanet J Rare Dis"},{"key":"2882_CR23","unstructured":"ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT03193476. Registry for patients with X-linked hypophosphatemia (XLH Registry). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03193476 Accessed Nov 2021."},{"key":"2882_CR24","unstructured":"European Medicines Agency. ICH: E 6 (R2): Guideline for good clinical practice (ICH GCP). https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf. Accessed Nov 2021."},{"key":"2882_CR25","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/. Accessed Nov 2021."},{"key":"2882_CR26","doi-asserted-by":"publisher","unstructured":"Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis. J Clin Endocrinol Metab. 2020;105:e871\u20138. https:\/\/doi.org\/10.1210\/clinem\/dgz203.","DOI":"10.1210\/clinem\/dgz203"},{"key":"2882_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","volume":"87","author":"EM Curtis","year":"2016","unstructured":"Curtis EM, van der Velde R, Moon RJ, van den Bergh JPW, Geusens P, de Vries F, et al. Epidemiology of fractures in the United Kingdom 1988\u20132012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone. 2016;87:19\u201326. https:\/\/doi.org\/10.1016\/j.bone.2016.03.006.","journal-title":"Bone"},{"key":"2882_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1507\/endocrj.EJ21-0386","volume":"69","author":"N Ito","year":"2022","unstructured":"Ito N, Kang HG, Nishida Y, Evins A, Skrinar A, Cheong HI. Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey. Endocr J. 2022;69:373\u201383. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0386.","journal-title":"Endocr J"},{"key":"2882_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","volume":"34","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, et al. High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR). J Bone Miner Res. 2019;34:490\u20136. https:\/\/doi.org\/10.1002\/jbmr.3614.","journal-title":"J Bone Miner Res"},{"key":"2882_CR30","doi-asserted-by":"publisher","first-page":"e210564","DOI":"10.1530\/EC-21-0564","volume":"11","author":"C Nguyen","year":"2022","unstructured":"Nguyen C, Celestin E, Chambolle D, Linglart A, Duplan MB, Chaussain C, et al. Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. Endocr Connect. 2022;11:e210564. https:\/\/doi.org\/10.1530\/EC-21-0564.","journal-title":"Endocr Connect"},{"key":"2882_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0022034520901719","volume":"99","author":"H Zhang","year":"2020","unstructured":"Zhang H, Chavez MB, Kolli TN, Tan MH, Fong H, Chu EY, et al. Dentoalveolar defects in the Hyp mouse model of X-linked hypophosphatemia. J Dent Res. 2020;99:419\u201328. https:\/\/doi.org\/10.1177\/0022034520901719.","journal-title":"J Dent Res"},{"key":"2882_CR32","doi-asserted-by":"publisher","first-page":"e42506","DOI":"10.1371\/journal.pone.0042506","volume":"7","author":"M Bonthuis","year":"2012","unstructured":"Bonthuis M, van Stralen KJ, Verrina E, Edefonti A, Molchanova EA, Hokken-Koelega AC, et al. Use of national and international growth charts for studying height in European children: development of up-to-date European height-for-age charts. PLoS ONE. 2012;7:e42506. https:\/\/doi.org\/10.1371\/journal.pone.0042506.","journal-title":"PLoS ONE"},{"key":"2882_CR33","doi-asserted-by":"publisher","unstructured":"Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen CY, San Martin J, et al. Growth curves for children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2020;105:3243\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgaa495.","DOI":"10.1210\/clinem\/dgaa495"},{"key":"2882_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1530\/EC-19-0481","volume":"9","author":"VV Zhukouskaya","year":"2020","unstructured":"Zhukouskaya VV, Rothenbuhler A, Colao A, Di Somma C, Kamenick\u00fd P, Trabado S, et al. Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. Endocr Connect. 2020;9:144\u201353. https:\/\/doi.org\/10.1530\/EC-19-0481.","journal-title":"Endocr Connect"},{"key":"2882_CR35","doi-asserted-by":"publisher","unstructured":"Mindler GT, Kranzl A, Stauffer A, Kocijan R, Ganger R, Radler C, et al. Lower limb deformity and gait deviations among adolescents and adults with X-linked hypophosphatemia. Front Endocrinol. 2021;12:754084. https:\/\/doi.org\/10.3389\/fendo.2021.754084.","DOI":"10.3389\/fendo.2021.754084"},{"key":"2882_CR36","doi-asserted-by":"publisher","first-page":"e036367","DOI":"10.1136\/bmjopen-2019-036367","volume":"10","author":"T Kubota","year":"2020","unstructured":"Kubota T, Fukumoto S, Cheong HI, Michigami T, Namba N, Ito N, et al. Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study. BMJ Open. 2020;10:e036367. https:\/\/doi.org\/10.1136\/bmjopen-2019-036367.","journal-title":"BMJ Open"},{"key":"2882_CR37","unstructured":"ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT03651505. X-linked hypophosphatemia disease monitoring program. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03651505. Accessed Nov 2021."},{"key":"2882_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s13023-021-02069-9","volume":"16","author":"MK Javaid","year":"2021","unstructured":"Javaid MK, Mordenti M, Boarini M, Sangiorgi L, Group EBW, Westerheim I, et al. Patients\u2019 priorities and expectations on an EU registry for rare bone and mineral conditions. Orphanet J Rare Dis. 2021;16:463. https:\/\/doi.org\/10.1186\/s13023-021-02069-9.","journal-title":"Orphanet J Rare Dis"},{"key":"2882_CR39","doi-asserted-by":"publisher","first-page":"152.e1-e12","DOI":"10.1016\/j.medcli.2021.07.029","volume":"159","author":"D Gonz\u00e1lez-Lamu\u00f1o","year":"2022","unstructured":"Gonz\u00e1lez-Lamu\u00f1o D, Lorente Rodr\u00edguez A, Luis Yanes MI, Mar\u00edn-Del Barrio S, Mart\u00ednez D\u00edaz-Guerra G, Peris P. Clinical practice recommendations for the diagnosis and treatment of X-linked hypophosphatemia: a consensus based on the ADAPTE method. Med Clin. 2022;159:152.e1-e12. https:\/\/doi.org\/10.1016\/j.medcli.2021.07.029.","journal-title":"Med Clin"},{"key":"2882_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s12889-021-10606-1","volume":"21","author":"B Iyen","year":"2021","unstructured":"Iyen B, Weng S, Vinogradova Y, Akyea RK, Qureshi N, Kai J. Long-term body mass index changes in overweight and obese adults and the risk of heart failure, cardiovascular disease and mortality: a cohort study of over 260,000 adults in the UK. BMC Public Health. 2021;21:576. https:\/\/doi.org\/10.1186\/s12889-021-10606-1.","journal-title":"BMC Public Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02882-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02882-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02882-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T07:08:24Z","timestamp":1700464104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02882-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02882-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2358387\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This registry is run in accordance with the recommendations from the Declaration of Helsinki and has received ethical, regulatory and institutional approvals at national, regional and site level for each participating country, as required. All participants or their legal representative provide informed consent before their enrolment in the registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GA has received honoraria for consultancy and for lecturing in educational activities from Kyowa Kirin International. SSBN has received honoraria for providing consultancy from Kyowa Kirin International; and research grants, in addition to honoraria, for providing consultancy from Inozyme Pharma. AMB has received research grants and honoraria for providing consultancy and lectures from Kyowa Kirin International. MLB has received honoraria from Amgen, Bruno Farmaceutici S.p.A., Calcilytix, Kyowa Kirin International and UCB Pharma; grants and\/or speaker fees from Abiogen Pharma, Alexion, Amgen, Bruno Farmaceutici S.p.A., Echolight, Eli Lilly and Company, Kyowa Kirin International, SPA, Theramex and UCB Pharma; and consultancy fees from Alexion, Amolyt Pharma, Bruno Farmaceutici S.p.A., Calcilytix, Kyowa Kirin International and UCB Pharma. KB has received honoraria as a consultant from Amgen, Kyowa Kirin International, Theramex and UCB Pharma. CLC has received honoraria for consultancy and for lecturing in educational activities from Kyowa Kirin International. FE has received honoraria from Chiesi Farmaceutici, Kyowa Kirin International and Recordati Rare Diseases; grants and\/or speaker fees from Chiesi Farmaceutici, Kyowa Kirin International and Recordati Rare Diseases; and consultant fees from Alnylam, AVROBIO, Kyowa Kirin International and Otsuka. SG has no competing interests to declare. DH has received consultancy and speaker fees from Chiesi Farmaceutici and Kyowa Kirin International; and research grants from Amgen, Chiesi Farmaceutici and Kyowa Kirin International. RK has received honoraria from Kyowa Kirin International for advisory board participation. EL has received consultancy fees from Kyowa Kirin International. OM has received honoraria as a consultant from BridgeBio, Kyowa Kirin International and Ultragenyx. MZM has received honoraria for attending advisory boards and for educational lectures\/webinars from Kyowa Kirin International. ON has received consultancy honoraria and research funding from Kyowa Kirin International. DS serves as a consultant for Kyowa Kirin Germany; and has received honoraria for attending advisory boards from Kyowa Kirin International. LTS has received honoraria as a consultant from Amgen and Kyowa Kirin International. JL and AW are employees of Kyowa Kirin International. SW was an employee of Kyowa Kirin International at the time of drafting this manuscript. MCZ reports that her institution has received a research grant from Kyowa Kirin International.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}